RxDoctor Payments Data

Candice Moore

Family · Arlington, TXNPI 1972043131

Payments from drug & device makers

$2,117in general payments, 2019–2025

Across 119 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$350
  • Boehringer Ingelheim$328
  • AbbVie$325
  • Sanofi-aventis U.S. LLC$202
  • Lilly USA, LLC$143
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$143
  • plus $625 from 10 others

What the payments were for

  • Food & beverage$2,117100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,117 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$11,090
Medicare patients
33
Services billed
157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$56,637
RybelsusSemaglutide20$46,959
JardianceEmpagliflozin25$31,596
FarxigaDapagliflozin Propanediol24$31,564
TrulicityDulaglutide14$24,078
JanuviaSitagliptin Phosphate12$19,347
MounjaroTirzepatide15$17,762
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$7,826
SymbicortBudesonide/Formoterol Fumarate18$4,289
Fluticasone Propionate52$901
Nifedipine ErNifedipine37$870
Atorvastatin Calcium127$796
Omeprazole35$782
Gabapentin39$673
Losartan Potassium64$610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$350$103,59561 claims
Lilly USA, LLCTrulicity, Mounjaro$143$41,84129 claims
AstraZenecaFarxiga, Symbicort$80$35,85342 claims
Boehringer IngelheimJardiance$328$31,59625 claims
MerckJanuvia$81$19,34712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →